Takeaways
#- DePablos identified approximately $17.75 as Teva’s breakout test, with a possible larger objective near $31.
- He preferred a Parsons pullback toward $85 instead of chasing the shares around $92.
- Rocket Companies had held a retest of its breakout, but the advance brought more overhead levels into view.
- Appian’s reported insider activity did not substitute for a base or stronger price action.
Teva Pharmaceutical Industries (TEVA) had spent years trying to recover from a severe decline. On the August 13, 2024 Chart Request Live, Alfonso DePablos saw a tight trading range that could finally help resolve that long base. His reference was approximately $17.75.
Patrick Dunuwila agreed that the chart had become interesting, especially where the consolidation met VWAP anchored to the old high. Yet the same session included strong stocks they preferred to buy on a pullback and a weak stock they were unwilling to buy merely because insiders reportedly were.
Teva’s long base narrowed into a tight range
DePablos described a rounded bottom developing over roughly five years after the stock’s prolonged decline. The recent compression in its trading range stood out against that larger formation.
He liked the setup above approximately $17.75 and identified a possible objective near $31. The target also aligned with the area preceding a large 2017 gap down. Dunuwila thought that history could matter if the stock returned there: investors who had been underwater for years might use the recovery to sell.
The setup therefore had two different time horizons. The tight range provided a nearer breakout test, while the larger base offered the potential for a much more substantial recovery. DePablos emphasized that a reversal of that size could still take time to develop.
Parsons was strong, but the entry had moved away
Parsons (PSN) was already in an uptrend following a major base breakout. Its latest consolidation had resolved higher with a gap, leaving approximately $85 as the area DePablos wanted buyers to defend.
With the stock around $92, he preferred waiting for a retest. Buying there would put him between the intended entry and a potential target, making the balance of risk and reward less attractive. A fall back below $85 would return the stock to the earlier range.
Dunuwila agreed that waiting made more sense. He discussed the possibility of using the gap’s low as a nearby reference for an immediate entry, but preferred another opportunity closer to the breakout area. Their favorable view of the trend did not settle the separate question of what price they wanted to pay.
Rocket Companies had already tested its breakout
Rocket Companies (RKT) showed the kind of follow-through they wanted from a reversal. A breakout had cleared former highs and VWAP anchored to the old peak. The stock then tested the area from above, held it and advanced again.
DePablos placed the earlier trade reference around $15. By the recording, the stock was approaching other historical levels, including the area around $20. A retracement measurement and old price history made that a place to watch for possible resistance.
They liked the improving trend and the successful retest. The move’s progress also meant that someone entering later faced a different setup from the trader who had bought near the original breakout.
Appian still lacked the price confirmation they wanted
A viewer asked about Appian (APPN) and insider buying. The shares were pressing near multiyear lows, with a support area around $28–$29. DePablos could identify the level, but he did not like the long setup. He preferred to see a base develop.
Dunuwila offered a more tactical possibility: wait for a reclaim of $30, then use the recent lows as a reference. He also preferred buying strength.
Both treated insider activity as a reason to investigate a company, rather than sufficient reason to purchase it. For Appian, they wanted the chart to confirm that buyers were gaining control before relying on the reported buying as part of a bullish case.
Questions and answers
#Questions about the original 2024-08-13 episode.
Why was the $31 area important for Teva?
It combined a projected recovery objective with price history before the large 2017 gap down. Dunuwila thought investors who had held through that decline could create selling pressure if the stock returned there.
Why wait for a Parsons pullback despite its uptrend?
DePablos wanted an entry closer to the $85 breakout reference. Around $92, the stock was farther from that level and between his preferred entry and a potential target.
What additional evidence did they want in Appian?
DePablos wanted a base to form. Dunuwila considered a reclaim of $30 as a possible tactical trigger. Both wanted stronger price behavior rather than relying only on reported insider buying.
Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .